Alembic Pharmaceuticals Ltd Q1 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
No
0 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →US business expected to grow 10%-15% for the full year, supported by volume gains and product launches (4 launched in Q1, 10-15 planned for rest of the year).
- →Rest of World (RoW) generics saw 21% growth in Q1; expected to grow 10%-15% for the full year.
- →India business aims to return to double-digit growth within months; currently working on improving execution and aligning with market norms.
- →New manufacturing facilities ramp-up and cost optimization initiatives expected to improve operating leverage and margins.
- →API business has been muted but showing potential for recovery after pricing pressures stabilize.
- →Overall 10% year-on-year revenue growth achieved in Q1, with broad-based growth despite pricing pressures.
See what Alembic Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- →No specific mention of any new fundraising through debt or equity during the call.
- →Gross debt as of June 30, 2025, stands at Rs. 1,185 crores and net debt at Rs. 967 crores, broadly similar to March levels.
- →Future debt movement is expected to depend on working capital needs and business growth trajectory.
- →Management is cautious and will reassess debt reduction or increases in upcoming quarters based on US market dynamics.
- →No indication of equity fundraising discussed in the call.
See what Alembic Pharmaceuticals Ltd management said on order book — free account, 30 seconds.
Capex plans
No- →Most new capacity augmentation projects have been completed.
- →Current CAPEX is primarily directed towards maintenance, replacement, and debottlenecking wherever necessary.
- →There is very little CAPEX planned for major expansion or upgrades at this time.
- →The company guided for a CAPEX of about Rs. 400 crores for the year, which will be capitalized incrementally over the quarters.
- →Depreciation expense increased due to commissioning of a new indoor manufacturing facility for the blended business.
- →Future CAPEX impact on depreciation will be reflected as and when assets are capitalized.
- →No large capital allocation planned for setting up manufacturing in the US due to pricing pressure and uncertain tariff impacts.
Track Alembic Pharmaceuticals Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- →US business expected to grow 10-15% for the full year FY'26, supported by new product launches and market share gains.
- →Rest of the World (RoW) markets anticipated to grow 10-15% for the full year.
- →EBITDA margins before R&D increased by 23% year-on-year, reflecting revenue growth, better gross margin, and improved utilization.
- →R&D expenses increased as per plan, supporting future product pipeline.
- →Net profit grew 15% year-on-year in Q1 FY'26, with EPS rising from Rs. 6.84 to Rs. 7.85.
- →Maintenance CAPEX primarily, with limited expansion, implying focus on operational efficiency rather than aggressive capacity buildup.
- →Debt levels stable, with careful working capital management; debt trajectory to be reassessed in coming quarters.
- →Domestic business aiming to return to strong double-digit growth after current challenges.
- →Overall, management projects sustainable growth driven by execution, new launches, and market expansion.
Order book
How does Alembic Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureSee full Pharmaceuticals & Biotechnology sector rankings
How does Alembic Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Alembic Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY26) on revenue, margins and earnings-call signals.
Continue your research
What Alembic Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Ind-Swift Laboratories Ltd (Q1 FY27)
Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14). Key concall takeaways from Ind-Swift…
- HIKAL (Q1 FY27)
400 crores revenue by FY30, with sustained strong customer demand and portfolio expansion. Key concall takeaways from Hikal Ltd's Q1 FY27 earnings call — and…